Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3014% below fair value
$21.01+0.36 (+1.74%)
Close on Nov 18, 2026Market cap $2.17BP/E –Yield –
Beam Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Beam Therapeutics's price to sales ratio was 17.1× on Nov 11, 2026, against 46.1× a year earlier. Over the last 5 years it ranged from 4.6× to 103.3×, with a median of 26.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 17.1× | −33.4 |
| 2025 | Dec 31, 2025 | 50.4× | +44.6 |
| 2024 | Dec 31, 2024 | 5.9× | −20.6 |
| 2023 | Dec 29, 2023 | 26.5× | −3.5 |
| 2022 | Dec 30, 2022 | 30.0× | – |
See a number that looks wrong?